CTTH CTT PHARMACEUTICAL HOLDINGS, INC.
Pharmaceutical Preparations · OTC · SEC CIK 1035422 · Fiscal year ends 12/31
Financial factors as of 2015-09-30 (2015Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-1,345.6%
TTM EPS YoY-500.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-207.0%
ROA-146.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets20.0%
Debt / equity0.00x
Current ratio—
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.17x
Accruals ratio-121.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2025-09-302025-09-30 | 2015Q32015-09-30 | 2015Q22015-06-30 | 2015Q12015-03-31 | 2014Q4*2014-12-31 | 2014Q32014-09-30 | 2014Q22014-06-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| SG&A expense | $2,314 | $9,374 | $14,934 | $4,466 | $34,882 | $4,573 | $12,946 | $916 |
| Operating income | — | — | — | — | -$337,052 | — | — | -$22,322 |
| Net income | -$127,064 | -$15,379 | -$341,930 | -$362,657 | -$337,052 | $271,481 | -$43,196 | -$920 |
| EPS (basic) | — | — | -0.03 | 0.00 | -0.02 | — | -0.01 | 0.00 |
| EPS (diluted) | 0.00 | 0.00 | -0.03 | 0.00 | -0.02 | — | -0.01 | 0.00 |
| Weighted avg. shares (diluted) | 60.70M | 57.33M | 21.32M | 21.32M | 19.51M | — | 15.77M | 14.92M |
| Balance sheet | ||||||||
| Cash & equivalents | $12,625 | $30,544 | $32,121 | $46,073 | $73,447 | $81,179 | $125,318 | $3,669 |
| Receivables | — | — | $5,430 | $5,430 | $5,430 | $5,430 | $5,430 | $5,429 |
| Current assets | $12,625 | — | $922,038 | $958,688 | $1.04M | $1.05M | — | — |
| Intangibles | $65,701 | — | — | — | — | — | — | — |
| Total assets | $78,326 | — | $922,038 | $1.18M | $1.42M | $1.66M | $130,748 | $227,543 |
| Current liabilities | $37,347 | — | — | — | — | — | — | — |
| Total liabilities | $37,347 | — | $183,960 | $156,373 | $211,696 | $169,490 | $124,600 | $141,987 |
| Shareholders' equity | $40,979 | $81,760 | $738,078 | $1.03M | $1.21M | $1.49M | $6,148 | $85,556 |
| Shares outstanding | 61.52M | — | 21.32M | 21.32M | 19.51M | 19.51M | 184.37M | 35.18M |
| Cash flow statement | ||||||||
| Operating cash flow | -$17,405 | -$12,405 | -$15,527 | -$29,158 | -$39,652 | -$46,837 | $20,869 | -$28,737 |
| Investing cash flow | — | — | — | — | — | -$1 | $271,069 | -$147,689 |
| Financing cash flow | $29,999 | $15,000 | -$959 | $2,787 | $28,550 | — | -$386,750 | $386,750 |
| Stock-based compensation | — | — | $46,408 | $49,166 | $43,650 | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 24 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.